Ultrasound Model to Help Differentiate Between Placenta Accreta Spectrum and Uterine Dehiscence in 3rd Trimester Pregnancies

November 14, 2025 updated by: Mostafa Ahmed Mohammed Refaat Askalany, Assiut University

Placenta Accreta Spectrum VS Uterine Scar Dehiscence: Accurate Ultrasound Model in 3rd Trimester Pregnancies for Percise Diagnosis

By using 2d Ultrasound on 3rd trimester pregnant women, a model is made to help differentiate between placenta accreta spectrum and uterine scar dehiscence before operative action to help prepare multi-disciplinary steps if needed

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

A cross-sectional observational study

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Female patients admitted to women health hospital, Assiut university, Assiut

Description

Inclusion Criteria:

  • Women in 3rd trimester pregnancy with low lying placenta previa
  • History of 1 or more C-section
  • Patients planning to deliver baby in Assiut women health hospital
  • Willing and able to participate

Exclusion Criteria:

  • Antepartum Hemorrhage(sever attack) as it hinders time for accurate diagnosis and calling expert team of diagnosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Placental site
Time Frame: (gestational age 28wk-full term) till operation
(gestational age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental thickness
Time Frame: (gestational age 28wk- full term) till operation
(gestational age 28wk- full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental size
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental lacunae
Time Frame: (gestational age 28wk-full term) till operation
(gestational age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone
Time Frame: (gestattional age 28wk-full term) till operation
(gestattional age 28wk-full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries
Time Frame: (gestational age 28wks-full term) till time of operation
(gestational age 28wks-full term) till time of operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface
Time Frame: (gestational age 28wks- full term) till operation
(gestational age 28wks- full term) till operation
Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface
Time Frame: (gestational age 28wks- full term) ill operation
(gestational age 28wks- full term) ill operation

Secondary Outcome Measures

Outcome Measure
Time Frame
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental site
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental size
Time Frame: (gestational age 28wk- full term)till the operation
(gestational age 28wk- full term)till the operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental thickness
Time Frame: (gestational age 28wk-full term) till operation
(gestational age 28wk-full term) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental lacunae
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone
Time Frame: (gestational age 28wks - fullterm) till operation
(gestational age 28wks - fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface
Time Frame: (gestational age 28wk- fullterm) till operation
(gestational age 28wk- fullterm) till operation
precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface
Time Frame: (gestational age 28wk-full term) till operation
(gestational age 28wk-full term) till operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2025

Primary Completion (Estimated)

November 15, 2026

Study Completion (Estimated)

December 15, 2026

Study Registration Dates

First Submitted

September 30, 2025

First Submitted That Met QC Criteria

November 14, 2025

First Posted (Actual)

November 19, 2025

Study Record Updates

Last Update Posted (Actual)

November 19, 2025

Last Update Submitted That Met QC Criteria

November 14, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 042025201333

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Placenta Accreta, Third Trimester

Clinical Trials on 2D ultrasound doppler

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe